Renerve Ltd
RNV
Company Profile
- Business description- Renerve Ltd specializes in developing a range of ready-to-use products that are cleaner, safer for repairing or replacing damaged peripheral nerves, resulting in good patient outcomes. Its product candidates include NervAlign Bionic Nerve, NervAlign Nerve Graft, and NervAlign Nerve Cuff [The NervAlign Nerve Guide Matrix, The NervAlign Nerve Conduit, The NervAlign Bionic Replacement Nerve]. The company operates in New Zealand and USA. Maximum of revenue is from USA. 
- Contact- 157 Heidelberg Road 
 NorthcoteVIC3070
 AUS- T: +61 394823940 
- Sector- Healthcare - Stock type- Defensive 
- Industry- Biotechnology - Fiscal Year End- 30 June 2026 - Employees
Stocks News & Analysis
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
We think Microsoft stock is moderately undervalued.
stocks
After earnings, is Tesla stock a buy, a sell, or fairly valued?
Q3 earnings reflected sequential improvement driven by record auto deliveries and energy storage deployments.
Morningstar Investment Ideas
Markets
| Index | Last price | Change | % Change | 
|---|---|---|---|
| All Ordinaries | 9,206.70 | 32.80 | 0.36% | 
| CAC 40 | 8,147.35 | 53.53 | -0.65% | 
| DAX 40 | 24,118.89 | 5.32 | -0.02% | 
| Dow JONES (US) | 47,522.12 | 109.88 | -0.23% | 
| FTSE 100 | 9,721.06 | 35.08 | -0.36% | 
| HKSE | 26,282.69 | 63.45 | -0.24% | 
| NASDAQ | 23,581.14 | 377.33 | -1.57% | 
| Nikkei 225 | 51,325.61 | 17.96 | 0.04% | 
| NZX 50 Index | 13,498.36 | 39.07 | 0.29% | 
| S&P 500 | 6,822.34 | 68.25 | -0.99% | 
| S&P/ASX 200 | 8,913.20 | 33.20 | 0.37% | 
| SSE Composite Index | 3,986.90 | 29.43 | -0.73% |